University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.  Please note we are currently on an enrollment hold for all GI Studies due to COVID-19.  Please reach out to us directly if you have questions about a specific study. 

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular and Biliary Tract
| ImmunotherapyNeuroendocrine | Non-therapeutic | Pancreatic
Opening Soon | All Cancer Trials at UCSF

COLORECTAL

 

 

CC#16452: Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu 

 

CC#174517: Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Contact: Renee Wang (415) 514-6258: Renee.Wang@ucsf.edu 

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu

 

CC#187015: A Phase II Study of Preoperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#19457: Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Contact: Sneha Nalla (415) 353-7284: Sneha.Nalla@ucsf.edu

 

EARLY PHASE

     

AMC095: A phase 1 study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

Contact: Nana Owusu-Kwarteng (415) 514-6363: Nana.Owusu-Kwarteng@ucsf.edu

  

CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors

Contact: Nana Owusu-Kwarteng (415) 514-6363: Nana.Owusu-Kwarteng@ucsf.edu

 

CC#169521: Combination Therapy of Rucaparib and Irinotecan in Cancers with Mutations in DNA Repair (Note: restricted to patients with defects in the following molecules: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54L)

Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu 

 

CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

 

CC#18952: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

 

CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies

Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu

 

CC#189510: Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies

Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu  

  

CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu   

 

CC#189514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.

Contact: Delaire Fattah (415) 514-9286: Delaire.Fattah@ucsf.edu  

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact: Lauren Wilch (415) 3553-3642: Lauren.Wilch@ucsf.edu  

 

CC#19954:  A Phase 1 Multicenter, Open-Label, Dose-Escalation an Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO_176

Contact: Delaire Fattah (415) 514-9286: Delaire.Fattah@ucsf.edu  

 

CC#19955: Protocol 101-18101 – An Open Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Contact: Osman Shokoor (415) 353-8449: Osman.Shokoor@ucsf.edu

 

CC#19956: Protocol RMC 4360 02: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 in combination with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu 

 

GASTRO ESOPHAGEAL

 

CC#17701: A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#18453: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Contact: Nancy Kaushal (415) 514-7633: Nancy.Kaushal@ucsf.edu 

 

CC#18955: A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu 

 

CC#189516: A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Subjects with locally advanced (unresectable) or metastatic solid tumor malignancy including but not limited to SCCHN, NSCLC, metastatic castration resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC) and gastric cancer, who have received prior therapy.

Contact:  Lauren Wilch (415) 3553-3642: Lauren.Wilch@ucsf.edu  

 

HEPATOCELLULAR and BILIARY TRACT

  

CC#15452: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant To Platinum-Based Chemotherapy

Contact: Maxine Hamilton (415) 476-3755: Maxine.Hamilton@ucsf.edu

 

CC#174523: A Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy

Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu

 

CC#184517: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Contact: Maxine Hamilton (415) 476-3755: Maxine.Hamilton@ucsf.edu

 

CC#194519: A Phase 3 Randomized, Double Blind Study of

Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Contact: Gar Singer (415) 353-9544: Gar.Singer@ucsf.edu

 

S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Contact: Alex Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

 

IMMUNOTHERAPY

 

CC#16702: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (MSI-H colorectal carcinomas)

Contact: Dhruba Biswas (415) 514-2259: Dhruba.Biswas@ucsf.edu 

 

CC#17701: A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers

Contact: Marissa Gin (415) 476-3816: Marissa.Gin@ucsf.edu

 

CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.

Contact: Eliot Lee (415) 476-1044:  Eliot.Lee@ucsf.edu

 

CC#187011:  A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers

Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu  

 

 

 

 

NEUROENDOCRINE TUMORS

 

CC#169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Contact: Melissa Lopez (415) 885-3728: Melissa.Lopez@ucsf.edu

 

CC#17459: Phase II Randomized Embolization Trial for Neuroendocrine Tumor Metastases to the Liver (RETNET) 

Contact: Shawn Cheng (415) 514-7632: Shawn.Cheng@ucsf.edu

 

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases

Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu

 

A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

 

 

 

 

NON-THERAPEUTIC

 

CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry

Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu

 

            CC#134510: GIMP: Molecular Profiling

            Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu    

           

            CC#134510: GIMP: Tissue GIMP & Blood GIMP (Collisson)

            Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu

 

            CC#134510: GIMP: PRRT in pNET

            Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu

           

CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study     (LOGIC)

            Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu      

           

CC#164519: Circulating Tumor Derived Cell-Free DNA as a Novel Biomarker to Predict Recurrence of Colorectal Cancer

Contact: Faaiz Ibrahim (415) 514-8101: Faaiz.Ibrahim@ucsf.edu

 

CC#174525: Self-Monitoring and Reminder Texts for Physical Activity after Cancer II (Smart Pace II)

Contact: Alexandra (Alex) Milloy (415) 502-3310: Alexandra.Milloy@ucsf.edu

 

CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer

Contact: Dalila Stanfield (415) 476-2976: Dalila.Stanfield@ucsf.edu  

 

CC#174535: A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma

            Contact: Karen Zhang (415) 502-1877: Karen.Zhang2@ucsf.edu

 

 

PANCREATIC

 

 

CC#174512: WO39608: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer) 

Contact: Nancy Kaushal (415) 514-7633: Nancy.Kaushal@ucsf.edu 

 

CC#187011:  A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers

Contact: Eliot Lee (415) 476-1044: Eliot.Lee@ucsf.edu   

 

CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu 

 

**************************************************

 

**TO BE OPENED WITHIN 3 MONTHS**

 

 

CC#194514: A Phase 2 Multicenter, Open-Label, Non-Randomized Study of Bavituximab Plus Pembrolizumab in Patients with Advanced Gastric or Gastroesophageal Cancer Who Have Progressed On or After At Least One Prior Standard Therapy

Contact: Taylor Sanchez (415) 885-7740: Taylor.Sanchez@ucsf.edu

 

CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer

Contact: Taylor Sanchez (415) 885-7740: Taylor.Sanchez@ucsf.edu

 

CC#20456: Precision Promise Platform Trial For Metastatic Pancreatic Cancer

Contact: Mikaela Esquivel (415) 353-7145: Mikaela.Esquivel@ucsf.edu

 

CC#199511: Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Pts. w/Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Lauren Wilch (415) 353-3642: Lauren.Wilch@ucsf.edu

CC#199516: Phase 1/1b Study of TPST-1120 () as Single Agent or w/Systemic Anti-Cancer Therapies in Pts w/Advanced Solid Tumors
Contact: Lily Stander (415) 353-4084: Lily.Stander@ucsf.edu 

CC#199512: Phase 1b Master Protocol Studying AMG510 in Subjects w/Advanced Solid Tumors w/KRAS G12C Mutation

Contact: Erika Zigman (415) 353-7381: Erika.Zigman@ucsf.edu

 

 

 


For information on Early Phase clinical trials not listed please contact:

Kamran Abri Lavasani (415) 514-6245: Kamran.AbriLavasani@ucsf.edu

For information on Immunotherapy trials not listed please contactAndrew Chon (415) 476-2351: Andrew.Chon@ucsf.edu